Healthcare Providers and Services
Company Overview of AmerisourceBergen Drug Corporation
AmerisourceBergen Drug Corporation provides pharmaceutical distribution and pharmacy management solutions to reduce costs, increase efficiency, and improve patient care for retail pharmacy, alternate care pharmacy, and hospital pharmacy markets. It offers distribution, pharmacy automation, professional, specialty distribution, customer, and off-site packaging services; and quality care, cost control, market growth, pharmacy consulting, and technology solutions. The company serves pharmaceutical manufacturers, consumer product manufacturers, non-healthcare goods and service providers, independent pharmacies, and chain pharmacies. The company was formerly known as AmeriSource Corporation and c...
1300 Morris Drive
Chesterbrook, PA 19087
Founded in 1985
Key Executives for AmerisourceBergen Drug Corporation
Compensation as of Fiscal Year 2015.
AmerisourceBergen Drug Corporation Key Developments
AmerisourceBergen Drug Corporation Promotes Robert P. Mauch to President
Feb 4 15
AmerisourceBergen Corporation announced that Robert P. Mauch, 48, PharmD, PhD, has been promoted to Executive Vice President and President of AmerisourceBergen Drug Corporation, effective immediately. Previously, Mauch served as AmerisourceBergen Drug Corporationâ s Senior Vice President and Chief Operating Officer. David W. Neu will transition from his previous role as President of AmerisourceBergen Drug Corporation to assume the newly created position of Executive Vice President of Retail Strategy and President of Good Neighbor Pharmacy.
PharMerica Corporation Provides Legal Update in its Lawsuit with AmerisourceBergen Drug Corporation
Nov 25 14
PharMerica Corporation commenced litigation against AmerisourceBergen Drug Corporation in the Jefferson County Circuit Court of Kentucky on September 10, 2014. After the Lawsuit was filed in Kentucky, Amerisource commenced litigation against the Corporation in the Court of Chancery in the State of Delaware in an attempt to have the case heard in Delaware rather than Kentucky. On November 10, 2014, the Delaware Court of Chancery ruled that it did not have subject matter jurisdiction over the matter because Amerisource had filed the litigation in the incorrect court in Delaware. In so ruling, the Court of Chancery noted its belief that the case should be heard in Kentucky and not Delaware, while noting that the Delaware Superior Court would ultimately decide that issue. On November 20, 2014, the parties to the Delaware action stipulated to its voluntary dismissal. Following the commencement of the Lawsuit, Amerisource unilaterally instituted several changes to its obligations under the Amended and Restated Prime Vendor Agreement, as amended between the Corporation and Amerisource, which the Corporation believed were made in retaliation against the corporation for commencing the Lawsuit and seeking to enforce its rights under its Prime Vendor Agreement. On October 8, 2014, the Corporation filed a Motion for a Temporary Injunction against Amerisource to prohibit Amerisource from imposing automatic drug substitution programs on its transactions with the Corporation. The court heard the Motion for Temporary Injunction on November 13, 2014. On November 24, 2014, the court issued a temporary injunction against Amerisource. The temporary injunction will remain in effect for the duration of the litigation between the Corporation and Amerisource. Amerisource will have 20 days to appeal the injunction to the Kentucky Court of Appeals. The Corporation is pursuing claims for monetary damages that resulted from the actions of Amerisource upon which the injunction was based. At this time, the Corporation is unable to determine the ultimate impact of these litigation proceedings on its consolidated financial condition, results
of operations, or liquidity. The litigation proceedings with Amerisource could continue for an extended period
of time, likely longer than 18 months. Although the Corporation is confident in the merits of its case, until
the resolution or settlement of such proceedings, the Corporation cannot provide any assurances about the
collectability of the disputed amounts owed by Amerisource.
AmerisourceBergen Drug Corp. Wins $4.06 Billion Federal Contract
Nov 19 14
AmerisourceBergen Drug Corp. was awarded a federal contract valued at up to $4,055,350,448 by the Defense Logistics Agency Troop Support, Philadelphia, for prime vendor pharmaceutical and pharmaceutical-related products and support for worldwide distribution.
Similar Private Companies By Industry
Recent Private Companies Transactions